JMJeremiah D. Momper

Jeremiah D. Momper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeremiah D. Momper has a total of 68 co-authors. Here are the top co-authors by number of shared publications:

  • Anisha K. Nigam

    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA

    2 shared publications
  • Brookie M. Best

    Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego La Jolla CA USA

    2 shared publications
  • Mark Mirochnick

    Department of Pediatrics Boston University Chobanian & Avedisian School of Medicine Boston MA USA

    2 shared publications
  • Ahizechukwu C. Eke

    Division of Maternal‐Fetal Medicine Department of Gynecology and Obstetrics Johns Hopkins University School of Medicine Baltimore MD USA

    1 shared publication
  • Ahizechukwu Chigoziem Eke

    Johns Hopkins University School of Medicine

    1 shared publication
  • Alice Stek

    Division of Maternal‐Fetal Medicine Department of Obstetrics and Gynecology University of Southern California School of Medicine Los Angeles CA USA

    1 shared publication

Latest Publications

  • Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED

    by Tk Nguyen, Jung-Woo Chae, Lauren Ziemba, Anne Coletti, Kevin Knowles, Benjamin Johnston, Patrick Jean-Philippe, Tsungai Mhembere, Tariro Chawana, Deo Wabwire, et al.

    Background: Limited information is available on breast milk transfer and subsequent infant systemic exposure to dolutegravir (DTG), tenofovir alafenamide (TAF), and tenofovir (TFV). We evaluated concentrations of DTG, TAF, and TFV in maternal and infant plasma and breast milk from participants of International Maternal Pediatric Adolescent AIDS Clinical Trials 2010, a clinical trial that enrolled women initiating either a DTG-containing or an efavirenz-containing antiretroviral treatment regimen during pregnancy. Methods: Time-matched postpartum maternal and infant samples were collected at 6 weeks postpartum. Validated assays quantitated concentrations of DTG, TAF, and TFV. Relative infant dose was estimated using an average milk intake of 150 mL/kg/d and observed breast milk concentrations. Results: Data were available from 192 postpartum lactating women and their breastfed infants. Median maternal plasma concentrations of DTG, TAF, and TFV were 2810, 0.0, and 96 ng/mL, respectively. For DTG, median [interquartile range (IQR)] concentrations in breast milk and infant plasma were 91 ng/mL (67–123) and 69 ng/mL (41–95), respectively. TAF was below the quantitative limit (BQL) in nearly all breast milk and infant plasma samples. For TFV, median (IQR) concentrations in breast milk were 8 ng/mL (6–12), and nearly all infant plasma samples were BQL. The median RIDs of DTG, TAF, and TFV from breastfeeding were 1.9%, 0.00%, and 0.03%, respectively. Conclusions: Breast milk transfer of DTG, TAF, and TFV is low and results in minimal systemic exposure in breastfed infants. The clinical relevance of infant exposure to low concentrations of these antiretrovirals—particularly DTG—is unknown but should be considered in the context of the risk of drug resistance in infants who acquire HIV.

  • Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure

    by Steven Sun, Mina Nikanjam, Mark Mirochnick, Kathleen M. Powis, Ahizechukwu C. Eke, Alice Stek, Priyanka Arora, Tim R. Cressey, Kristina M. Brooks, Brookie M. Best, et al.

    Bictegravir is an integrase strand transfer inhibitor available in fixed‐dose combination with emtricitabine and tenofovir alafenamide for HIV treatment. The objectives of this study were to develop a population pharmacokinetic model for bictegravir during pregnancy and postpartum, identify main drivers of between‐subject variability, and evaluate the role of adherence patterns in maintaining therapeutic exposure. Intensive bictegravir concentration–time data were used from IMPAACT 2026, a pharmacokinetic study of selected antiretroviral drugs during pregnancy and postpartum. Five hundred and eight bictegravir plasma concentrations from 27 participants during the second and third trimesters of pregnancy and postpartum were utilized for model development. A one‐compartment structural model best described bictegravir PK. Pregnancy increased bictegravir apparent clearance (CL/F) by 61% compared to postpartum, while Black/African American race was associated with a 32% increase in apparent volume of distribution (Vd/F). Plasma albumin concentrations were associated with a 43% decrease in CL/F and body weight was associated with a 120% increase in Vd/F over the range of observed values. Monte Carlo simulations predicted median (90% prediction interval) pre‐dose bictegravir concentrations of 920 ng/mL (265–2081) during the third trimester and 3399 ng/mL (1423–6391) postpartum, exceeding the protein‐adjusted 95% effective concentration (162 ng/mL). Adherence simulations predicted a single missed dose at steady‐state during the third trimester results in 43.7% of virtual subjects with concentrations below pharmacodynamic target, while two consecutive missed doses result in 90.4% with concentrations below target. These results show that while standard bictegravir dosing is effective during pregnancy, consistent adherence is critical to maintain effective therapeutic exposures.


  • Open Access

    Subtherapeutic Meropenem Antibiotic Exposure in Children With Septic Shock Assessed by Noncompartmental Pharmacokinetic Analysis in a Prospective Dataset

    by John S. Md Bradley, Helen Harvey, Dayna Bs Stout, Jeremiah Momper, Edmund Capparelli, Sean N. PharmD Avedissian, Courtney Barbato, Robert H. MD Mak, Tom P. Jones, Douglas Do Jones, et al.

    OBJECTIVES: To define meropenem plasma concentrations and pharmacodynamic exposure metrics in children with septic shock during the first 3 days of PICU hospitalization. DESIGN: Pharmacokinetic sampling was undertaken in 19 subjects receiving standard meropenem dosing (20 mg/kg/dose, 8 hr) recruited from March 2019 to March 2022. Sampling occurred once each day following meropenem given 24 hours apart, during the first 3 PICU days. Data analysis was completed in 2023 and noncompartmental analysis was performed to assess pharmacodynamic exposure targets for sepsis. Clearance and volume of distribution at 20 mg/kg/dose were used to simulate mean exposures at 40 and 60 mg/kg/dose. SETTING: PICU in a tertiary care center. SUBJECTS: Patients 4 weeks old or older with hypotension requiring fluid resuscitation and vasopressor therapy, receiving meropenem as empiric therapy for sepsis. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Augmented renal clearance (ARC) was documented in eight of 19 subjects, previously associated with subtherapeutic plasma concentrations, while three of 19 had acute kidney injury and decreased renal clearance. When assessed by pharmacodynamic exposure targets for sepsis (plasma meropenem concentrations above the minimum inhibitory concentration [MIC] of Pseudomonas aeruginosa for 70% or 100% of the dosing interval), ten of 19 and nine of 19 children, respectively, had subtherapeutic plasma meropenem exposures during PICU day 1, even for pathogens with an MIC considered “susceptible” by U.S. Food and Drug Administration criteria. Therapeutic meropenem pharmacodynamic exposures were associated with a positive 24-hour fluid balance on PICU day 1 and a negative 24-hour fluid balance by day 3, although profound variability was noted in fluid administered and renal output. CONCLUSIONS: Given the variability in meropenem systemic exposure in pediatric septic shock, therapeutic drug monitoring, or monitoring for ARC, is suggested during the first days of hospitalization to allow daily assessments of dosing needs to achieve pharmacodynamic exposure targets for sepsis.


  • Open Access

    Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

    by Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐Yeol Yun, Jung‐Woo Chae, Jeremiah D. Momper

    Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity. Therefore, the prediction of drug–drug interactions (DDIs) and estimation of dosing requirements for concomitantly administered drugs is imperative. In this study, we aimed to develop a physiologically‐based PK (PBPK) model for RTV using the PK‐sim® software platform. A total of 13 clinical PK studies of RTV covering a wide dose range (100 to 600 mg including both single and multiple dosing), and eight clinical DDI studies with RTV on CYP3A and P‐gp substrates, including alprazolam, midazolam, rivaroxaban, clarithromycin, fluconazole, sildenafil, and digoxin were used for the model development and evaluation. Chronopharmacokinetic differences (between morning vs. evening doses) and limitations in parameter estimation for biochemical processes of RTV from in vitro studies were incorporated in the PBPK model. The final developed PBPK model predicted 100% of RTV AUClast and Cmax within a twofold dimension error. The geometric mean fold error (GMFE) from all PK datasets was 1.275 and 1.194, respectively. In addition, 97% of the DDI profiles were predicted with the DDI ratios within a twofold dimension error. The GMFE values from all DDI datasets were 1.297 and 1.212, respectively. Accordingly, this model could be applied to the prediction of DDI profiles of RTV and CYP3A substrates and used to estimate dosing requirements for concomitantly administered drugs.


  • Open Access

    Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients

    by Jeremiah D. Momper, Raman Venkataramanan, Arin S. Jantz, Diane M. Cibrik, Kelly Md Birdwell, Tk Nguyen, Brian M. Masters, Samir J. Patel

    Background: For extended-release drug formulations, effective half-life (t1/2eff) is a relevant pharmacokinetic parameter to inform dosing strategies and time to reach steady state. Tacrolimus, an immunosuppressant commonly used for the prophylaxis of organ rejection in transplant patients, is available as both immediate- and extended-release formulations. To the best of our knowledge, the t1/2eff of tacrolimus from these different formulations has not yet been assessed. The objective of this study was to characterize the t1/2eff and terminal half-life (t1/2z) of an extended-release once-daily tacrolimus formulation (LCPT) and twice-daily immediate-release tacrolimus (IR-Tac). Methods: A noncompartmental analysis of pharmacokinetic data obtained from a phase 2 study in de novo kidney transplant recipients receiving either LCPT or IR-Tac was conducted. Intensive blood sampling was performed on days 1, 7, and 14, and tacrolimus whole blood concentrations were measured using a validated liquid chromatography with tandem mass spectrometry method. T1/2eff was estimated using within-participant accumulation ratios. T1/2z was estimated by linear regression of the terminal phase of the concentration versus time profile. Results: The median accumulation ratios of LCPT and IR-Tac on day 14 were 3.18 and 2.06, respectively. The median (interquartile range; IQR) t1/2eff for LCPT at day 14 of dosing was 48.4 (37.4–77.9) hours, whereas the t1/2z was 20.3 (17.6–22.9) hours. For IR-Tac, the median (IQR) t1/2eff and t1/2z on day 14 were 12.5 (8.8–23.0) hours and 12.2 (9.2–15.7) hours, respectively. Conclusions: Consistent with its prolonged release of tacrolimus, LCPT demonstrated a higher accumulation ratio and a longer t1/2eff compared with IR-Tac. These findings underscore the pharmacokinetic differences between different drug formulations of the same moiety and may help inform dose adjustments for LCPT in kidney transplantation.


  • Open Access

    In Vivo Regulation of Small Molecule Natural Products, Antioxidants, and Nutrients by OAT1 and OAT3

    by Kian Falah, Patrick Zhang, Anisha K. Nigam, Koustav Maity, Geoffrey Chang, Jeffry C. Granados, Jeremiah D. Momper, Sanjay K. Nigam

    The organic anion transporters OAT1 (SLC22A6) and OAT3 (SLC22A8) are drug transporters that are expressed in the kidney, with well-established roles in the in vivo transport of drugs and endogenous metabolites. A comparatively unexplored potential function of these drug transporters is their contribution to the in vivo regulation of natural products (NPs) and their effects on endogenous metabolism. This is important for the evaluation of potential NP interactions with other compounds at the transporter site. Here, we have analyzed the NPs present in several well-established databases from Asian (Chinese, Indian Ayurvedic) and other traditions. Loss of OAT1 and OAT3 in murine knockouts caused serum alterations of many NPs, including flavonoids, vitamins, and indoles. OAT1- and OAT3-dependent NPs were largely separable based on a multivariate analysis of chemical properties. Direct binding to the transporter was confirmed using in vitro transport assays and protein binding assays. Our in vivo and in vitro results, considered in the context of previous data, demonstrate that OAT1 and OAT3 play a pivotal role in the handling of non-synthetic small molecule natural products, NP-derived antioxidants, phytochemicals, and nutrients (e.g., pantothenic acid, thiamine). As described by remote sensing and signaling theory, drug transporters help regulate redox states by meditating the movement of endogenous antioxidants and nutrients between organs and organisms. Our results demonstrate how dietary antioxidants and other NPs might feed into these inter-organ and inter-organismal pathways.


  • Open Access

    Distinguishing Molecular Properties of OAT, OATP, and MRP Drug Substrates by Machine Learning

    by Anisha K. Nigam, Jeremiah D. Momper, Anupam Anand Ojha, Sanjay K. Nigam

    The movement of organic anionic drugs across cell membranes is partly governed by interactions with SLC and ABC transporters in the intestine, liver, kidney, blood–brain barrier, placenta, breast, and other tissues. Major transporters involved include organic anion transporters (OATs, SLC22 family), organic anion transporting polypeptides (OATPs, SLCO family), and multidrug resistance proteins (MRPs, ABCC family). However, the sets of molecular properties of drugs that are necessary for interactions with OATs (OAT1, OAT3) vs. OATPs (OATP1B1, OATP1B3) vs. MRPs (MRP2, MRP4) are not well-understood. Defining these molecular properties is necessary for a better understanding of drug and metabolite handling across the gut–liver–kidney axis, gut–brain axis, and other multi-organ axes. It is also useful for tissue targeting of small molecule drugs and predicting drug–drug interactions and drug–metabolite interactions. Here, we curated a database of drugs shown to interact with these transporters in vitro and used chemoinformatic approaches to describe their molecular properties. We then sought to define sets of molecular properties that distinguish drugs interacting with OATs, OATPs, and MRPs in binary classifications using machine learning and artificial intelligence approaches. We identified sets of key molecular properties (e.g., rotatable bond count, lipophilicity, number of ringed structures) for classifying OATs vs. MRPs and OATs vs. OATPs. However, sets of molecular properties differentiating OATP vs. MRP substrates were less evident, as drugs interacting with MRP2 and MRP4 do not form a tight group owing to differing hydrophobicity and molecular complexity for interactions with the two transporters. If the results also hold for endogenous metabolites, they may deepen our knowledge of organ crosstalk, as described in the Remote Sensing and Signaling Theory. The results also provide a molecular basis for understanding how small organic molecules differentially interact with OATs, OATPs, and MRPs.


  • Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy

    by Engie Salama, Ahizechukwu C. Eke, Brookie M. Best, Mark Mirochnick, Jeremiah D. Momper

    Pharmacokinetic boosting of antiretroviral (ARV) therapies with either ritonavir or cobicistat is used to achieve target drug exposure, lower pill burden, and provide simplified dosing schedules. Several ARVs require boosting, including the integrase inhibitor elvitegravir as well as protease inhibitors such as darunavir, atazanavir, and lopinavir. The use of boosted regimens in pregnant women living with HIV has been studied for a variety of ARVs; however, a recent recommendation by the US Food and Drug Administration advised against cobicistat‐boosted regimens in pregnancy due to substantially lower drug exposures observed in clinical pharmacokinetic studies. The objectives of this article are to review pharmacokinetic enhancement of ARVs with ritonavir and cobicistat during pregnancy and postpartum, describe clinical implications, and provide recommendations for future research.